Clinical application of the minimal residual disease monitoring in canine lymphoma

据报道，标准化疗后的总生存期长达1年。在本研究中，我们通过实时荧光定量PCR对化疗后的微小残留病（MRD）进行量化，客观地评估化疗方案的疗效。通过MRD监测结果，我们可以提出药物剂量的改变、巩固化疗的需要、完全缓解期早期再诱导化疗的必要性等改进化疗方案的策略。可以想象，目前的研究非常有助于改善犬淋巴瘤的化疗方式，并表明犬淋巴瘤作为人类非霍奇金淋巴瘤动物模型的有效性。

Overall survival durations after standard chemotherapies have been reported as long as 1 year. In the present study, we assessed the efficacy of the chemotherapeutic protocols objectively by quantification of the minimal residual disease, MRD, after chemotherapy with real-time PCR. Through the results of MRD monitoring, we could propose several strategies to improve the chemotherapeutic protocols such as dose change of the drugs, requirement of the consolidation chemotherapy, and the necessity of the early re-induction chemotherapy during complete remission. The present studies were conceivably very helpful to improve the chemotherapeutic modalities for canine lymphoma as well as indicative of the usefulness of canine lymphoma as an animal model for human non-Hodgkin lymphoma.